This human clinical pilot study from 2008 set the basis of future research in whether benfotiamine in combination with α-lipoic acid would normalize markers of reactive oxygen species-induced pathways of complications in humans. Authors found the intervention with oral benfotiamine plus α-lipoic acid normalises several complications-causing pathways in patients with type 1 diabetes.
References:
Du, X., Edelstein, D., & Brownlee, M. (2008). Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia, 51(10), 1930–1932. https://doi.org/10.1007/s00125-008-1100-2
